Advances in intravesical therapy for urinary tract disorders

References

• Zargar H, Aning J, Ischia J, et al. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(4):220–230. DOI:10.1038/nrurol.2014.52.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Kashyap MP, Kawamorita N, et al. Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome. ISRN Pharmacol. 2014;2014:601653. DOI:10.1155/2014/601653.
   PubMedGoogle Scholar
• Rajaganapathy BR, Jayabalan N, Tyagi P, et al. Advances in therapeutic development for radiation cystitis. LUTS. 2014;6(1):1–10. DOI:10.1111/luts.12045.
   Web of Science ®Google Scholar
• Kuo HC, Liu HT, Chuang YC, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117–1124. DOI:10.1016/j.eururo.2014.01.036.
   PubMed Web of Science ®Google Scholar
• Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis–a practical approach. Urology. 1997;49(5A Suppl):105–107.
   PubMed Web of Science ®Google Scholar
• Eldrup J, Thorup J, Nielsen SL, et al. Permeability and ultrastructure of human bladder epithelium. Br J Urol. 1983;55(5):488–492.
   PubMedGoogle Scholar
• Parsons CL, Boychuk D, Jones S, et al. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol. 1990;143(1):139–142.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Hensley H, Jacobs J, et al. Non-invasive imaging of near infrafred dye labeled liposomes facilitates evaluation of bioresidence time. J Urol. 2010;183(4):e628. DOI:10.1016/j.juro.2010.02.1406.
   Google Scholar
• Tyagi S, Tyagi P, Van-le S, et al. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol. 2006;176(4 Pt 1):1673–1678. S0022-5347(06)01533-3 [pii]. DOI:10.1016/j.juro.2006.06.088.
   PubMed Web of Science ®Google Scholar
• Saban MR, Backer JM, Backer MV, et al. VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol. 2008;295(1):F60–72. DOI:10.1152/ajprenal.00618.2007.
   PubMedGoogle Scholar
• Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65(2):238–242.
   PubMed Web of Science ®Google Scholar
• Shirley SW, Stewart BH, Mirelman S. Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders. Urology. 1978;11(3):215–220.
   PubMedGoogle Scholar
• Ghoniem GM, McBride D, Sood OP, et al. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy. World J Urol. 1993;11(3):178–182.
   PubMed Web of Science ®Google Scholar
• Birder LA, Kanai AJ, de Groat WC. DMSO: effect on bladder afferent neurons and nitric oxide release. J Urol. 1997;158(5):1989–1995.
   PubMed Web of Science ®Google Scholar
• Childs SJ. Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis. Urol Clin North Am. 1994 Feb;21(1):85–88.
   PubMed Web of Science ®Google Scholar
• Santos NC, Figueira-Coelho J, Martins-Silva J, et al. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003;65(7):1035–1041.
   PubMed Web of Science ®Google Scholar
• Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–39.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Takano Y, Toshitani S. Systemic contact dermatitis medicamentosa occurring after intravesical dimethyl sulfoxide treatment for interstitial cystitis. Arch Dermatol. 1988;124(2):182–183.
   PubMed Web of Science ®Google Scholar
• Abramov Y, Goldberg RP, McGuire M, et al. Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide. Urology. 2004;63(6):1182–1183.
   PubMed Web of Science ®Google Scholar
• Biggers RD. Self-administration of dimethyl sulfoxide (DMSO) for interstitial cystitis. Urology. 1986;28(1):10–11.
   PubMed Web of Science ®Google Scholar
• Shurafa M, Shumaker E, Cronin S. Prostaglandin F2-alpha bladder irrigation for control of intractable cyclophosphamide-induced hemorrhagic cystitis. J Urol. 1987;137(6):1230–1231.
   PubMed Web of Science ®Google Scholar
• Trigg ME, O’Reilly J, Rumelhart S, et al. Prostaglandin E1 bladder instillations to control severe hemorrhagic cystitis. J Urol. 1990;143(1):92–94.
   PubMed Web of Science ®Google Scholar
• Miller LJ, Chandler SW, Ippoliti CM. Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. Ann Pharmacother. 1994;28(5):590–594.
   PubMed Web of Science ®Google Scholar
• Hindley RG, Brierly RD, Thomas PJ. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int. 2004;93(1):89–92.
   PubMed Web of Science ®Google Scholar
• Lai MC, Kuo YC, Kuo HC. Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol. 2013;20(2):203–207. DOI:10.1111/j.1442-2042.2012.03135.x.
   PubMed Web of Science ®Google Scholar
• Gulpinar O, Haliloglu AH, Gokce MI, et al. Instillation of hyaluronic acid via electromotive drug administration can improve the efficacy of treatment in patients with interstitial cystitis/painful bladder syndrome: a randomized prospective study. Korean J Urol. 2014;55(5):354–359. DOI:10.4111/kju.2014.55.5.354.
   PubMedGoogle Scholar
• Gulpinar O, Kayis A, Suer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014;8(9–10):E610–4. DOI:10.5489/cuaj.2036.
   PubMed Web of Science ®Google Scholar
• Zabkowski T, Jurkiewicz B, Saracyn M. Treatment of recurrent bacterial cystitis by intravesical instillations of hyaluronic acid. Urol J. 2015;12(3):2192–2195.
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.
   PubMed Web of Science ®Google Scholar
• Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994;152(5 Pt 1):1641–1645.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–782.
   PubMed Web of Science ®Google Scholar
• Chen D, Song D, Wientjes MG, et al. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res. 2003;9(1):363–369.
   PubMed Web of Science ®Google Scholar
• Hsieh JT, Zhou J, Gore C, et al. R11, a novel cell-permeable peptide, as an intravesical delivery vehicle. BJU Int. 2011; 108(10):1666–1671. DOI:10.1111/j.1464-410X.2011.10185.x.
   PubMed Web of Science ®Google Scholar
• Gontero P, Cattel L, Paone TC, et al. Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int. 2010; 106(11):1652–1656. DOI:10.1111/j.1464-410X.2010.09496.x.
   PubMed Web of Science ®Google Scholar
• Palou J, Carcas A, Segarra J, et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol. 2004;172(2):485–488. DOI:10.1097/01.ju.0000131770.14409.7f.
   PubMed Web of Science ®Google Scholar
• Gao X, Au JL, Badalament RA, et al. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res. 1998;4(1):139–143.
   PubMed Web of Science ®Google Scholar
• Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release. 2002;78(1–3):81–95.
   PubMed Web of Science ®Google Scholar
• Elman NM, Patta Y, Scott AW, et al. The next generation of drug-delivery microdevices. Clin Pharmacol Ther. 2009;85(5):544–547. clpt20094 [pii]. DOI:10.1038/clpt.2009.4.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra00. DOI:10.1126/scitranslmed.3003804.
   Web of Science ®Google Scholar
• Farokhzad OC, Dimitrakov JD, Karp JM, et al. Drug delivery systems in urology–getting “smarter”. Urology. 2006;68(3):463–469. S0090-4295(06)00499-7 [pii]. DOI:10.1016/j.urology.2006.03.069.
   PubMed Web of Science ®Google Scholar
• Lee H, Cima MJ. An intravesical device for the sustained delivery of lidocaine to the bladder. J Control Release. 2011;149(2):133–139. DOI:10.1016/j.jconrel.2010.10.016.
   PubMed Web of Science ®Google Scholar
• Knudsen BE, Chew BH, Denstedt JD. Drug-eluting biomaterials in urology: the time is ripe. BJU Int. 2005;95(6):726–727. DOI:10.1111/j.1464-410X.2005.05388.x.
   PubMed Web of Science ®Google Scholar
• Jeong B, Bae YH, Kim SW. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. J Biomed Mater Res. 2000;50(2):171–177.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Li Z, Chancellor M, et al. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res. 2004;21(5):832–837.
   PubMed Web of Science ®Google Scholar
• Lin T, Zhang Y, Wu J, et al. A floating hydrogel system capable of generating CO2 bubbles to diminish urinary obstruction after intravesical instillation. Pharm Res. 2014;31(10):2655–2663. DOI:10.1007/s11095-014-1362-y.
   PubMed Web of Science ®Google Scholar
• Men K, Liu W, Li L, et al. Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system. Nanoscale. 2012;4(20):6425–6433. DOI:10.1039/c2nr31592k.
   PubMed Web of Science ®Google Scholar
• Chen JP, Leu YL, Fang CL, et al. Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin. J Pharm Sci. 2011;100(2):655–666. DOI:10.1002/jps.22309.
   PubMed Web of Science ®Google Scholar
• Truschel ST, Wang E, Ruiz WG, et al. Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell. 2002;13(3):830–846.
   PubMed Web of Science ®Google Scholar
• Rajaganapathy BR, Chancellor MB, Nirmal J, et al. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PloS one. 2015;10(3):e0122766. DOI:10.1371/journal.pone.0122766.
   PubMed Web of Science ®Google Scholar
• Frangos DN, Killion JJ, Fan D, et al. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. J Urol. 1990;143(6):1252–1256.
   PubMed Web of Science ®Google Scholar
• Johnson JW, Nayar R, Killion JJ, et al. Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Sel Cancer Ther. 1989;5(4):147–155.
   PubMedGoogle Scholar
• Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2(4):369–381.
   PubMedGoogle Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13(12):527–537.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice. FEBS Lett. 1974;45(1): 71–74.
   PubMed Web of Science ®Google Scholar
• Lee S, Dausch S, Maierhofer G, et al. A new therapy concept for the treatment of dry eye–the usefulness of phospholipid liposomes. Klin Monatsbl Augenheilkd. 2004;221(10):825–836.
   PubMed Web of Science ®Google Scholar
• Dausch D, Lee S, Dausch S, et al. Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes. Klin Monatsbl Augenheilkd. 2006;223(12):974–983.
   PubMed Web of Science ®Google Scholar
• Peters KM, Hasenau D, Killinger KA, et al. Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. Int Urol Nephrol. 2014;46(12):2291–2295. DOI:10.1007/s11255-014-0828-5.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182(4):1393–1400. DOI:10.1016/j.juro.2009.06.024.
   PubMed Web of Science ®Google Scholar
• Stremmel W, Merle U, Zahn A, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005;54(7):966–971. 54/7/966 [pii]. DOI:10.1136/gut.2004.052316.
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–650.
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977–982. discussion 82-3. DOI:10.1097/01.ju.0000169481.42259.54.
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–222. DOI:10.1016/j.juro.2008.03.028.
   PubMed Web of Science ®Google Scholar
• Mandal M, Lee KD. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta. 2002;1563(1–2):7–17.
   PubMed Web of Science ®Google Scholar
• Caccin P, Rossetto O, Rigoni M, et al. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett. 2003;542(1–3):132–136.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009;182(2):786–792. DOI:10.1016/j.juro.2009.03.083.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172(4 Pt 1):1529–1532.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang HY, et al. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol Urodyn. 2011;30(3):421–427. DOI:10.1002/nau.20981.
   PubMed Web of Science ®Google Scholar
• Nirmal J, Tyagi P, Chancellor MB, et al. Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. J Urol. 2013;189(4):1553–1558. DOI:10.1016/j.juro.2012.10.123.
   PubMed Web of Science ®Google Scholar
• Rajaganapathy BR, Janicki JJ, Levanovich P, et al. Intravesical liposomal tacrolimus protects against radiation cystitis induced by 3-beam targeted bladder radiation. J Urol. 2015. DOI:10.1016/j.juro.2015.03.108.
   PubMed Web of Science ®Google Scholar
• Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye. 2008;22(6):761–767. eye200886 [pii]. DOI:10.1038/eye.2008.86.
   PubMed Web of Science ®Google Scholar
• Blietz CE, Thode B, Hauses M, et al. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In Vivo. 2009;23(1):13–19.
   PubMed Web of Science ®Google Scholar
• Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788(4):872–891. DOI:10.1016/j.bbamem.2008.11.005.
   PubMed Web of Science ®Google Scholar
• Huygens A, Kamuhabwa AR, Roskams T, et al. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells. J Urol. 2005;174(1):69–72. DOI:10.1097/01.ju.0000162037.49102.56.
   PubMed Web of Science ®Google Scholar
• Shorning BY, Griffiths D, Clarke AR, et al. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PloS one. 2011;6(1):e16209. DOI:10.1371/journal.pone.0016209.
   PubMedGoogle Scholar
• Beckel JM, Daugherty SL, Tyagi P, et al. Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder. J Physiol. 2015;593(8):1857–1871. DOI:10.1113/jphysiol.2014.283119.
   PubMed Web of Science ®Google Scholar
• Kashyap M, Kawamorita N, Tyagi V, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. J Urol. 2013;190(2):757–764. DOI:10.1016/j.juro.2013.02.090.
   PubMed Web of Science ®Google Scholar
• Nogawa M, Yuasa T, Kimura S, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 2005;115(4):978–985. DOI:10.1172/JCI23043.
   PubMed Web of Science ®Google Scholar
• Kang MR, Yang G, Place RF, et al. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res. 2012;72(19):5069–5079. DOI:10.1158/0008-5472.CAN-12-1871.
   PubMed Web of Science ®Google Scholar
• Fazel J, Rotzer S, Seidl C, et al. Fractionated intravesical radioimmunotherpy Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma. Cancer Biol Ther. 2015. DOI:10.1080/15384047.2015.1071735.
   PubMed Web of Science ®Google Scholar
• Li X, Choi WW, Yan R, et al. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PloS one. 2014;9(8):e105326. DOI:10.1371/journal.pone.0105326.
   PubMedGoogle Scholar
• Martin DT, Steinbach JM, Liu J, et al. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. Mol Cancer Ther. 2014;13(1):71–81. DOI:10.1158/1535-7163.MCT-13-0502.
   PubMed Web of Science ®Google Scholar
• Martin DT, Hoimes CJ, Kaimakliotis HZ, et al. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine. 2013;9(8):1124–1134. DOI:10.1016/j.nano.2013.05.017.
   PubMed Web of Science ®Google Scholar
• Erdogar N, Iskit AB, Eroglu H, et al. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. Int J Pharm. 2014;471(1–2):1–9. DOI:10.1016/j.ijpharm.2014.05.014.
   PubMed Web of Science ®Google Scholar
• Mugabe C, Matsui Y, So AI, et al. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res. 2011;17(9):2788–2798. DOI:10.1158/1078-0432.CCR-10-2981.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186(2):448–451. DOI:10.1016/j.juro.2011.03.129.
   PubMed Web of Science ®Google Scholar
• Wang BL, Gao X, Men K, et al. Treating acute cystitis with biodegradable micelle-encapsulated quercetin. Int J Nanomedicine. 2012;7:2239–2247. DOI:10.2147/IJN.S29416.
   PubMed Web of Science ®Google Scholar
• Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol. 2006;46(4):456–460. DOI:10.1177/0091270006286849.
   PubMed Web of Science ®Google Scholar
• Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn. 1999;18(5): 447–453.
   PubMed Web of Science ®Google Scholar
• Krause P, Fuhr U, Schnitker J, et al. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol. 2013;190(5):1791–1977. DOI:10.1016/j.juro.2013.05.011.
   PubMed Web of Science ®Google Scholar
• Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65(1):45–48.
   PubMed Web of Science ®Google Scholar
• Lee JE, Lim HJ. LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus. Mol Biol Rep. 2012;39(2):1079–1086. DOI:10.1007/s11033-011-0834-y.
   PubMed Web of Science ®Google Scholar
• Petrou SP, Parker AS, Crook JE, et al. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clinic Proc. 2009;84(8):702–706. DOI:10.1016/S0025-6196(11)60520-X.
   PubMed Web of Science ®Google Scholar
• Guo C, Yang B, Gu W, et al. Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis. PloS one. 2013;8(12):e82591. DOI:10.1371/journal.pone.0082591.
   PubMedGoogle Scholar
• Kim JC, Park EY, Hong SH, et al. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol. 2005;12(10):875–880. DOI:10.1111/j.1442-2042.2005.01140.x.
   PubMed Web of Science ®Google Scholar
• Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol. 2002;20(4):957–965.
   PubMed Web of Science ®Google Scholar
• Slobodov G, Feloney M, Gran C, et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171(4):1554–1558.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Smith PP, Kuchel GA, et al. Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol. 2014;46(Suppl 1):S11–21. DOI:10.1007/s11255-014-0808-9.
   PubMedGoogle Scholar
• Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn. 2010;29(3):408–412. DOI:10.1002/nau.20765.
   PubMed Web of Science ®Google Scholar
• Aizawa N, Wyndaele JJ, Homma Y, et al. Effects of TRPV4 cation channel activation on the primary bladder afferent activities of the rat. Neurourol Urodyn. 2012;31(1):148–155. DOI:10.1002/nau.21212.
   PubMed Web of Science ®Google Scholar
• Jang SW, Liu X, Chan CB, et al. Deoxygedunin, a natural product with potent neurotrophic activity in mice. PLoS One. 2010;5(7):e11528. DOI:10.1371/journal.pone.0011528.
   PubMedGoogle Scholar
• Jang SW, Liu X, Chan CB, et al. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009;16(6):644–656. DOI:10.1016/j.chembiol.2009.05.010.
   PubMed Web of Science ®Google Scholar
• Praveen Kumar V, Gajendra Reddy R, Vo DD, et al. Synthesis and neurite growth evaluation of new analogues of honokiol, a neolignan with potent neurotrophic activity. Bioorg Med Chem Lett. 2012;22(3):1439–1444. DOI:10.1016/j.bmcl.2011.12.015.
   PubMed Web of Science ®Google Scholar
• Cardenas DD, Ditunno JF, Graziani V, et al. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord. 2014;52(1):70–76. DOI:10.1038/sc.2013.137.
   PubMed Web of Science ®Google Scholar
• Corcoran AT, Yoshimura N, Tyagi V, et al. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–246. DOI:10.1007/s00345-012-0852-y.
   PubMed Web of Science ®Google Scholar
• Bouchelouche K, Alvarez S, Horn T, et al. Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha. Urology. 2006;67(1):214–219.
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Smaldone MC, Tyagi V, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010;17(1):4989–4994.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010;42(3):629–635. DOI:10.1007/s11255-009-9647-5.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Killinger K, Tyagi V, et al. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–2248. DOI:10.1016/j.juro.2012.01.034.
   PubMed Web of Science ®Google Scholar
• Birder LA, Wolf-Johnston A, Griffiths D, et al. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn. 2007;26(3):405–409. DOI:10.1002/nau.20372.
   PubMed Web of Science ®Google Scholar
• Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009;103(12):1668–1672. DOI:10.1111/j.1464-410X.2009.08380.x.
   PubMed Web of Science ®Google Scholar
• Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008;72(1):104–108. discussion 08. DOI:10.1016/j.urology.2008.01.069.
   PubMed Web of Science ®Google Scholar
• Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009. BJU8675 [pii]. DOI:10.1111/j.1464-410X.2009.08675.x.
   Web of Science ®Google Scholar
• Antunes-Lopes T, Carvalho-Barros S, Cruz CD, et al. Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol. 2011;2011:382431. DOI:10.1155/2011/382431.
   PubMedGoogle Scholar
• Desireddi NV, Campbell PL, Stern JA, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol. 2008;179(5):1857–1861. discussion 61-2. DOI:10.1016/j.juro.2008.01.028.
   PubMed Web of Science ®Google Scholar
• Agarwal M, He C, Siddiqui J, et al. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–581. DOI:10.1002/pros.22597.
   PubMed Web of Science ®Google Scholar